KLK3 and cancer: The relevant outcomes measured in the eligible studies included overall and cancer-specific mortality reported as hazard ratios, quality of life measured through questionnaires (FACIT-G, SF-36, EPIC-26, EPIC-CP, FACT-P, MAX-PC, and Rotterdam symptom checklist), serum PSA (ng/mL), PSAdt (months), and recurrence reported as hazard ratios.